

=> b reg
 FILE 'REGISTRY' ENTERED AT 10:15:16 ON 01 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2008 HIGHEST RN 1076692-21-1
 DICTIONARY FILE UPDATES: 28 NOV 2008 HIGHEST RN 1076692-21-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 19
 L7 STR



VAR G1=O/S
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E5 C E1 N AT 6

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
 L9 80 SEA FILE=REGISTRY SSS FUL L7

100.0% PROCESSED 11980 ITERATIONS 80 ANSWERS
 SEARCH TIME: 00.00.01

=> b hcap
 FILE 'HCAPLUS' ENTERED AT 10:15:23 ON 01 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the

the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Dec 2008 VOL 149 ISS 23
FILE LAST UPDATED: 30 Nov 2008 (20081130/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitrn 112 tot

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS ON SIN
 AN 2005:67296 HCAPLUS
 DN 143:172906
 TI Preparation of tetraazabenzosazulene derivatives as vasopressin V1a
 antagonists
 IN Ryckmans, Thomas
 DA Pfizer Limited, UK; Pfizer Inc.
 SO PCT Int. Appl., 53 pp.
 COCEN: PFX32
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-2005068466	A1	20050728	2005WO-1B0000263	20050105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, PO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TE, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MG, NA, SD, SL, SE, TE, UG, ZM, ZW, AM, AZ, BY, EG, GZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SR, TD, TG				
CA-----2554382	A1	20050728	2005CA-002554382	20050105
EP-----1706409	A1	20061004	2005EP-000702410	20050105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR--2005006848	A	20070612	2005BR-000006848	20050105
JP--2007317857	T	20070705	2006JP-000548476	20050105
MX-2006007563	A	20060907	2006MX-PA0007563	20060629
US-20070167430	A1	20070719	2007US-000588878	20070322
PRAI 2004GB-000000700	A	20040113		
2004US-00544866P	P	20040213		
2005WO-1B0000263	W	20050105		
OS CASREACT 143:172906; MARPAT 143:172906				
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [X = NR or O (wherein R = H, alkyl or SO₂alkyl); W = N or CH; Y and Y1 = H, halo, OH, CF₃, OCF₃, CN, NH₂ alkyl, alkoxy or cycloalkyl; Ring A = a heterocyclic ring containing at least one N atom; Z = a direct link, alkyl or cycloalkyl; R1 = R2, OR2, NCOR2, SR4, etc.; R2, R4 = H, cycloalkyl, CF₃, Ar or Het; Ar represents an aromatic ring, optionally fused to a heterocyclic ring, and/or optionally substituted with one or more groups; Het represents a heterocyclic ring optionally substituted with one or more groups, and/or optionally fused to an aromatic ring which is optionally substituted with one or more groups], useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease, were prepared. Thus, reacting 3-methoxybenzoic acid with the amine II (preparation given) afforded 39% III. Some of the compds. I were synthesized as a library. All the exemplified compds. I showed a Ki value of less than 500 nM when tested in screen 1.0 (VIA filter binding assay).

II 860769-49-9P 860769-50-2P 860769-51-3P
 860769-52-4P 860769-53-5P 860769-54-6P
 860769-55-7P 860769-56-8P 860769-57-9P
 860769-58-0P 860769-59-1P 860769-60-4P
 860769-61-5P 860769-62-6P 860769-63-7P
 860769-64-8P 860769-65-9P 860769-66-0P
 860769-67-1P 860769-68-2P 860769-69-3P

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)

860769-70-6P 860769-71-7P 860769-72-8P
 860769-73-9P 860769-74-0P 860769-75-1P
 860769-76-2P 860769-77-3P 860769-78-4P
 860769-79-5P 860769-80-6P 860769-81-9P
 860769-82-0P 860769-83-1P 860769-84-2P
 860769-85-3P 860769-86-4P 860769-87-5P
 860769-88-6P 860769-89-7P 860769-90-0P
 860769-91-1P 860769-92-2P 860769-93-3P
 860769-94-4P 860769-95-5P 860769-96-6P
 860769-97-7P 860769-98-8P 860769-99-9P
 860770-00-SP 860770-01-0P 860770-02-1P
 860770-03-2P 860770-04-3P 860770-05-4P
 860770-06-5P 860770-07-6P 860770-09-8P
 860770-11-2P 860770-13-4P 860770-15-6P
 860770-17-8P 860770-19-0P 860770-21-4P
 860770-23-6P 860770-25-8P 860770-27-0P
 860770-29-2P 860770-31-6P 860770-33-8P
 860770-35-0P 860770-37-2P 860781-08-4P
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (prepn. of tetraazabenzosazulene derivs. as vasopressin V1a antagonists)
 IT 860770-39-4P 860770-41-8P 860770-43-0P
 860770-45-2P 860770-46-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tetraazabenzosazulene derivs. as vasopressin V1a antagonists)
 IT 860769-49-9P
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (preparation of tetraazabenzosazulene derivs. as vasopressin V1a antagonists)
 RN 860769-49-9 HCAPLUS
 CN Methanone, 4-(4-chloro-5,6-dihydro-5-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-1-piperidinyl-1H-indol-3-yl- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 10:15:42 ON 01 DEC 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 10:15:42 ON 01 DEC 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:15:42 ON 01 DEC 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l13 tot
```

L13 ANSWER 1 OF 1 USPATFULL on STN
 AN 2007191249 USPATFULL
 TI Compounds useful in therapy
 IN Ryckmans, Thomas, Kent, UNITED KINGDOM
 PI US-20070167430 Al 20070719
 AI 2005US-000588878 Al 20050105 (10)
 2005WO-1B0000263 20050105
 PRAI 2004GB-000000700 20070322 PCT 371 date
 2004US-000544866P 20040213 (60)
 DT Utility
 FS APPLICATION
 LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,
 10017-5612, US
 CLAIM Number of Claims: 15
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN,CNT 1690


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein: X represents NR or O; R represents hydrogen, C.sub.1-8 alkyl or SO.sub.2, left brkt-bot, C.sub.1-8 alkyl, right brkt-bot.; W represents R or CH; Y and Z independently represent hydrogen, halogen, OH, CF.sub.3, OCF.sub.3, CN, NH.sub.2 C.sub.1-8 alkyl, C.sub.1-8 alkyloxy or C.sub.3-8cycloalkyl; Ring A represents a heterocyclic ring containing at least one nitrogen atom; Z represents a direct link, C.sub.1-8 alkyl or C.sub.3-8 cycloalkyl; R.sub.1 represents R.sub.2, OR.sub.2, OR.sub.3--R.sub.4, N(R.sub.2) [C.sub.1-8 alkylene].sub.aR.sub.4; NCO, R.sub.2, or SR.sub.4; R.sub.2 and R.sub.4 independently represent hydrogen, C.sub.3-8 cycloalkyl, CF.sub.3, Ar or Het; R.sub.3 represents a direct link or C.sub.1-8 alkyl; is 0 or 1; Ar represents an aromatic ring, optionally fused to a heterocyclic ring, and/or optionally substituted with one or more groups as described below; Het represents a heterocyclic ring optionally substituted with one or more groups as described below, and/or optionally fused to an aromatic ring which is optionally substituted with one or more groups as described below; at each occurrence C.sub.1-8alkyl, C.sub.1-8alkylene and C.sub.3-8cycloalkyl may be independently optionally substituted with one or more groups as described below; substituent groups for Ar, Het, C.sub.1-8alkyl, C.sub.1-8alkylene and C.sub.3-8cycloalkyl referred to the above are independently selected from hydrogen, halogen, C.sub.1-8alkyl, C.sub.1-8alkyloxy, S(C.sub.1-8alkyl), CN, CF.sub.3, NH.sub.2 and OH; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

II 860769-49-9P 860769-50-2P 860769-51-3P
 860769-52-4P 860769-53-5P 860769-54-6P
 860769-55-7P 860769-56-8P 860769-57-9P
 860769-58-0P 860769-59-1P 860769-60-4P
 860769-61-5P 860769-62-6P 860769-63-7P
 860769-64-8P 860769-65-9P 860769-66-0P
 860769-67-1P 860769-68-2P 860769-69-3P
 860769-70-6P 860769-71-7P 860769-72-8P
 860769-73-9P 860769-74-0P 860769-75-2P
 860769-76-2P 860769-77-3P 860769-78-4P
 860769-79-5P 860769-80-8P 860769-81-9P
 860769-82-0P 860769-83-1P 860769-84-2P
 860769-85-3P 860769-86-4P 860769-87-5P
 860769-88-6P 860769-89-7P 860769-90-0P
 860769-91-1P 860769-92-2P 860769-93-3P
 860769-94-4P 860769-95-5P 860769-96-6P
 860769-97-7P 860769-98-8P 860769-99-9P
 860770-00-9P 860770-01-0P 860770-02-1P
 860770-03-2P 860770-04-3P 860770-05-4P
 860770-06-5P 860770-07-6P 860770-08-7P

L13 ANSWER 1 OF 1 USPATFULL on STN (Continued)
 860770-11-2P 860770-12-4P 860770-13-6P
 860770-17-8P 860770-19-0P 860770-21-4P
 860770-23-6P 860770-25-8P 860770-27-0P
 860770-29-2P 860770-31-6P 860770-33-8P
 860770-35-0P 860770-37-2P 860781-08-4P
 (prepn. of tetraazabenzazulene derivs. as vasopressin V1a antagonists)
 IT 860770-39-4P 860770-41-8P 860770-43-0P
 860770-45-2P 860770-46-3P
 (preparation of tetraazabenzazulene derivs. as vasopressin V1a antagonists)
 IT 860769-49-9P
 (preparation of tetraazabenzazulene derivs. as vasopressin V1a antagonists)
 RN 860769-49-9 USPATFULL
 CN Methanone, [4-(8-chloro-5,6-dihydro-5-methyl-4H-(1,2,4)triazolo[4,3-
 4][1,4]benzodiazepin-1-yl)-1-piperidinyl]-1H-indol-3-yl- (CA INDEX
 NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:06:27 ON 01 DEC 2008)

L1 FILE 'HCAPLUS' ENTERED AT 10:07:07 ON 01 DEC 2008
1 US20070167430/PN

FILE 'REGISTRY' ENTERED AT 10:07:22 ON 01 DEC 2008

L2 FILE 'HCAPLUS' ENTERED AT 10:07:22 ON 01 DEC 2008
TRA L1 1- RN : 100 TERMS

L3 FILE 'REGISTRY' ENTERED AT 10:07:23 ON 01 DEC 2008
100 SEA L2
L4 83 L3 AND NRRS>=3
L5 83 L4 AND NC5/ES
L6 81 L5 AND N2CNC-C6-NC2NC3/ES
L7 STR
L8 6 L7
L9 80 L7 FULL
SAV TEM J878C1/A L9
L10 80 L9 AND L3

L11 FILE 'HCAOLD' ENTERED AT 10:14:03 ON 01 DEC 2008
0 L9

L12 FILE 'HCAPLUS' ENTERED AT 10:14:08 ON 01 DEC 2008
1 L9

L13 FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 10:14:33 ON 01 DEC 2008
1 L9

=>